Ronald Asbury Andrews - Mar 15, 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
Chief Executive Officer, Director
Signature
/s/ Ronald Andrews
Stock symbol
OCX
Transactions as of
Mar 15, 2022
Transactions value $
$0
Form type
4
Date filed
3/17/2022, 09:24 PM
Previous filing
Jan 13, 2022
Next filing
Aug 18, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +300K $0.00 300K Mar 15, 2022 Common Stock 300K $1.15 Direct F1
transaction OCX Option to Purchase Common Stock Award $0 +200K $0.00 200K Mar 15, 2022 Common Stock 200K $1.15 Direct F2
transaction OCX Option to Purchase Common Stock Award $0 +375K $0.00 375K Mar 15, 2022 Common Stock 375K $1.15 Direct F3
transaction OCX Restricted Stock Units Award $0 +35K $0.00 35K Mar 15, 2022 Common Stock 35K $0.00 Direct F4
transaction OCX Restricted Stock Units Award $0 +500K $0.00 500K Mar 15, 2022 Common Stock 500K $0.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.
F2 Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date.
F3 Options vest subject to the Issuer's achievement of pre-defined product-related milestones and financial performance and corporate budget objectives in 2022. The number of options that will vest will be determined based on the Issuer's level of achievement in 2022 with respect to such pre-defined objectives. If such pre-defined objectives are not achieved at a minimum level, no vesting will occur and the options will be cancelled. Options will vest in annual installments over three years from the effective date of grant, if such pre-defined objectives have been achieved in 2022, subject to continuous service through the applicable vesting date.
F4 The restricted stock units shall vest upon the completion of one year of continuous service from the date of grant.
F5 The restricted stock units will vest immediately upon the Issuer's achievement with respect to pre-defined market capitalization objectives and product-related milestones during the period beginning on January 1, 2022 and ending on December 31, 2024, subject to continuous service through the applicable vesting date. The number of restricted stock units that will vest will be determined based on the Issuer's level of achievement with respect to such pre-defined milestones. If such pre-defined milestones are not achieved at a minimum level, no vesting will occur and the restricted stock units will be cancelled.